- TETRAZOLE-SUBSTITUTED PYRAZOLOPYRIMIDINE INHIBITORS OF JAK KINASES AND USES THEREOF
-
Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmac
- -
-
-
- PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS
-
Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
- -
-
-
- THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF
-
Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
- -
-
Paragraph 0328-0329
(2018/12/04)
-
- Fluorinated liquid crystal compounds and liquid crystal medium containing same
-
The invention relates to liquid crystal compounds having a terminal structure in accordance with formula 1, 2, 3 or 4: wherein A2, A3, X1 and X2 and are defined herein. The invention further relates liquid c
- -
-
-
- Diethers of m- or p-hydroxyphenol
-
Diethers of m- or p-hydroxyphenol, as well as the monoethers, are prepared by reacting m- or p-tert.-butoxyphenol of the formula II STR1 with a halogen compound in the presence of a hydroxide, carbonate and/or bicarbonate of an alkali metal or alkaline ea
- -
-
-